InvestSMART

Cleo Diagnostics Ltd (ASX: COV) - Announcements

Current share price for COV : $0.345 0.005 (1.43%)+

ASX company news and announcements for Cleo Diagnostics Ltd (COV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cleo Diagnostics Ltd (COV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cleo Diagnostics Ltd (COV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cleo Diagnostics Ltd (COV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$49 Appendix 4E and 2025 Annual Report 26 Aug 2025 4:48PM $0.360 $0.345 fallen by 4.17%
$49 COV Commences Health Economic Study-Support US Market Entry 18 Aug 2025 9:22AM $0.350 $0.345 fallen by 1.43%
$49 Restricted securities to be released from escrow 15 Aug 2025 4:24PM $0.350 $0.345 fallen by 1.43%
$49 Quarterly activities and cashflow report 21 Jul 2025 9:09AM $0.365 $0.345 fallen by 5.48%
$49 CLEO Strengthens FDA Submission - Access to US Biobank 25 Jun 2025 9:58AM $0.340 $0.345 risen by 1.47%
$49 Investor Webinar 18 Jun 2025 8:48AM $0.350 $0.345 fallen by 1.43%
$49 Corporate Presentation 12 Jun 2025 8:33AM $0.360 $0.345 fallen by 4.17%
$49 Cleo Advances with Completion of Alpha Testing 12 May 2025 10:17AM $0.380 $0.345 fallen by 9.21%
$49 CLEO to Fast Track Development of Ovarian Cancer Test 28 Apr 2025 9:09AM $0.440 $0.345 fallen by 21.59%
$49 Notification regarding unquoted securities - COV 24 Apr 2025 4:29PM $0.440 $0.345 fallen by 21.59%
$49 CLEO Receives A$845k Research and Development Tax Incentive 24 Apr 2025 11:15AM $0.450 $0.345 fallen by 23.33%
$49 Quarterly activities and cashflow report 11 Apr 2025 4:19PM $0.375 $0.345 fallen by 8%
$49 CLEO Delivers Commercial Development Milestone 18 Mar 2025 9:35AM $0.455 $0.345 fallen by 24.18%
$49 Appendix 4D and Half Yearly Accounts 27 Feb 2025 4:53PM $0.505 $0.345 fallen by 31.68%
$49 Clarification to ASX Price Query 17 Feb 2025 5:35PM $0.475 $0.345 fallen by 27.37%
$49 Price Query Response 7 Feb 2025 5:58PM $0.435 $0.345 fallen by 20.69%
$49 Quarterly activities and cashflow report 31 Jan 2025 3:25PM $0.355 $0.345 fallen by 2.82%
$49 CLEO Further Expands Ovarian Cancer Trial with Siles Health 10 Dec 2024 9:03AM $0.345 $0.345 fallen by 0%
$49 Results of Annual General Meeting 27 Nov 2024 11:50AM $0.355 $0.345 fallen by 2.82%
$49 The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial 27 Nov 2024 8:31AM $0.350 $0.345 fallen by 1.43%
$49 Quarterly activities and cashflow report 16 Oct 2024 4:27PM $0.335 $0.345 risen by 2.99%
$49 Letter to Shareholders 4 Oct 2024 10:29AM $0.350 $0.345 fallen by 1.43%
$49 Notice of Annual General Meeting/Proxy Form 4 Oct 2024 10:26AM $0.350 $0.345 fallen by 1.43%
$49 Notice Required Under ASX Listing Rule 3.13.1 23 Sep 2024 4:14PM $0.390 $0.345 fallen by 11.54%
$49 Cleo Commences U.S. Clinical Trials 6 Sep 2024 9:10AM $0.360 $0.345 fallen by 4.17%

51 - 75 of 153 results

Page 3 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.